Date: 2017-10-09
Type of
information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in Experimental Eye Research
Company: Thrombogenics (Belgium)
Product: THR-317
Action
mechanism:
- monoclonal antibody. THR-317 (anti-PIGF) is a recombinant human monoclonal antibody directed against the receptor-binding site of human placental growth factor (PlGF). The product is an ophthalmologic formulation of TB-403, that has been developed by the swedish biotech Bioinvent.
- THR-317 is a monoclonal antibody targeting placental growth factor (PlGF), which is being developed for the treatment of diabetic macular edema (DME) as a stand-alone or as a combination therapy with current anti-VEGF drugs. ThromboGenics is currently recruiting patients into a Phase II clinical trial for THR-317 in Europe. First data from this study are expected in Q1 2018.
Disease: diabetic macular edema, diabetic retinopathy
Therapeutic
area: Ophtalmological diseases
Country:
Trial
details:
Latest
news:
- • On October 9, 2017, ThromboGenics announced that preclinical data on its THR-317 have been published in Experimental Eye Research. Experimental Eye Research peer-reviewed ThromboGenics' pre-clinical studies designed to investigate inhibition of placental growth factor (PlGF) as a possible therapy for Diabetic Retinopathy (DR). The effect of the murine form of THR-317 was evaluated in various animal models by studying different DR disease hallmarks, including vascular leakage, inflammation, neurodegeneration, and fibrosis.
- In its overall conclusion, the authors confirm that the anti-PlGF antibody shared a common pharmacology towards vascular leakage in comparison to VEGF inhibitors which are currently the standard of care for DR. Anti-PlGF therapy might provide additional benefits in respect to the reduction of inflammation, the absence of a negative impact on the neuroretina, and the inhibition of fibrotic responses after retinal damage, as such supporting its therapeutic potential for treating DR.
- • On May 24, 2017, ThromboGenics announced that it will give a presentation on THR-317 at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting. The presentation “Targeting placental growth factor attenuates retinal permeability and inflammation in diabetic Akimba mice” which will be given by ThromboGenics’ scientist Dr. Tjing-Tjing Hu, will provide further pre-clinical evidence supporting the development of THR-317.
Is
general: Yes
